Book a Meeting

BetterBet™ Anti-EGFR On-Target Antibody (CAT#: AES-0622-ZP673) Datasheet

Target
EGFR
Description
Anti-EGFR antibody takes advantage of the enrichment of some small molecules such as ATP in the tumor microenvironment, and activates the antibody by using the small molecule as a medium, so that the antibody is specifically activated only in the tumor.
Applications
"On-target" tumor antigen binding
Technology
ATP-mediated antibody engineering technology

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced EGFR antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
epidermal growth factor receptor
Background
EGFR; epidermal growth factor receptor; ERBB; HER1; mENA; ERBB1; PIG61; NISBD2; proto-oncogene c-ErbB-1; cell growth inhibiting protein 40; erb-b2 receptor tyrosine kinase 1; cell proliferation-inducing protein 61; receptor tyrosine-protein kinase erbB-1; avian erythroblastic leukemia viral (v-erb-b) oncogene homolog
Description
Anti-EGFR antibody takes advantage of the enrichment of some small molecules such as ATP in the tumor microenvironment, and activates the antibody by using the small molecule as a medium, so that the antibody is specifically activated only in the tumor.

In the tumor microenvironment, ATP is released from necrotic, apoptotic and other tumor cells, so its concentration is higher than that of normal cells. On-Target Antibody takes advantage of the enrichment of ATP in the tumor microenvironment to activate the antibody with ATP as a medium, so that the antibody is specifically activated only in the tumor.

Related Products

Non-fucosylated Anti-Human EGFR (Nimotuzumab) Therapeutic Antibody (CAT#: BioBet-203ZP)
Highly Galactosylated Anti-EGFR (Zalutumumab) Antibody (CAT#: BioBet-GA-199ZP)
Highly Galactosylated Anti-EGFR (Nimotuzumab) Antibody (CAT#: BioBet-GA-203ZP)
BetterBet™ Anti-EGFR FcγRIIB Binding Enhanced Antibody (CAT#: AES-0622-ZP345)
Highly Galactosylated Anti-EGFR (Imgatuzumab) Antibody (CAT#: BioBet-GA-204ZP)
BetterBet™ Anti-EGFR Recycling Antibody (CAT#: AES-0622-ZP17)
Non-fucosylated Anti-Human EGFR (Futuximab) Therapeutic Antibody (CAT#: BioBet-205ZP)
Highly Galactosylated Anti-EGFR (Futuximab) Antibody (CAT#: BioBet-GA-205ZP)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany